FDA approval of a second acellular pertussis vaccine for use among infants and young children.
On December 30, 1996, the Food and Drug Administration (FDA) licensed Wyeth-Lederle Vaccines and Pediatrics to distribute a combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (ACEL-IMUNE) for all five doses of the diphtheria, tetanus, and pertussis vaccination series administered to infants and children aged 6 weeks-6 years (before the seventh birthday). Since December 1991, ACEL-IMUNE has been licensed for use as the fourth and fifth doses of the vaccination series among children aged 15 months-6 years who previously received three or four doses of diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine (DTP). ACEL-IMUNE is the second acellular pertussis-containing vaccine to be licensed for use in infants in the United States.
D002648:Child; D002675:Child, Preschool; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D017277:Drug Approval; D006801:Humans; D007223:Infant; D014481:United States; D014486:United States Food and Drug Administration; D014611:Vaccination
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines